Document is current

Article History

Received: 12 May 2020

Revised: 15 July 2020

Accepted: 30 July 2020

First Online: 25 August 2020

Ethics approval and consent to participate

: The study received approval from the Central Ethics Committees of “Rennes Ouest V” in France and Central Ethics Committee of “Institut Jules Bordet”, Brussels in Belgium. The study was performed in accordance with the Declaration of Helsinki. A written informed consent was obtained from each patient prior to study enrolment.

: Anonymised data set may be available from the corresponding author on request.

: C.L.T. participated in advisory boards from MSD, BMS, Merck Serono, GSK, Astra Zeneca, Nanobiotix, Roche, Rakuten, Seatlle Genetics and Celgene. C.G.R. received grant from BMS, consulting fees from Roche, BMS, Pierre Fabre and Erytech and support for travel from Roche, BMS, Pierre Fabre and MSD. P.A.C. received honoraria from Astra Zeneca, Amgen, EMD-serono, Novartis and Roche. J.-P.D., N.K., E.B., S.H., C.J., A.V.-S., V.C. and L.E. declared no conflict of interest. A.M., W.J., F.B., O.A., O.d.B., V.T.-J. and C.Z. are employees of Onxeo and have declared to have stock options from the company (Onxeo). H.T. was an employee of Onxeo. She has declared no conflict of interest.

: The trial was sponsored by Onxeo SAS, France. Costs for technical support, article processing and Open Access were funded by Onxeo SAS.